BioRestorative Therapies, Inc. (BRTX)

Market Cap	13.66M
Revenue (ttm)	401,000
Net Income (ttm)	-8.98M
Shares Out	7.50M
EPS (ttm)	-1.16
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	15,449
Open	1.830
Previous Close	1.800
Day's Range	1.810 - 1.840
52-Week Range	1.030 - 2.550
Beta	77.48
Analysts	Strong Buy
Price Target	18.00 (+888.69%)
Earnings Date	May 13, 2025

About BRTX

BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. It develops programs relate to the treatment of disc/spine disease and metabolic disorders. The company’s products pipeline comprises BRTX-100, a lead cell therapy candidate formulated from autologous cultured mesenchymal stem cells collected from the patient’s bone marrow, as well as used for the non-surgical treatment of painful lumbosacral disc disorders or as a complimentary therapeutic to ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1997
• Employees: 11
• Stock Exchange: NASDAQ
• Ticker Symbol: BRTX
• Website: https://www.biorestorative.com

Financial Performance

In 2024, BioRestorative Therapies's revenue was $401,000, an increase of 175.03% compared to the previous year's $145,800. Losses were -$8.98 million, -13.81% less than in 2023.

Analyst Forecast

According to one analyst, the rating for BRTX stock is "Strong Buy" and the 12-month stock price forecast is $18.0.

Price Target

$18.0

(888.69% upside)

Analyst Consensus: Strong Buy